Rybelsus is an oral form of semaglutide that is FDA-approved for type 2 diabetes
PLoS ONE 7 , e46781 (2012)
Of the 710 patients with Type 2 diabetes studied, the NAION incident was 8.9% for those taking semaglutide compared to 1.8% for those taking another kind of medication
Reported benefits (per available research): FDA-approved, clinical-trial-supported reduction of excess visceral abdominal fat in HIV-associated lipodystrophy, the only indication with robust human RCT evidence behind it Studied in a randomized, placebo-controlled trial for possible support of executive function and cognitive performance in healthy older adults and adults with mild cognitive impairment (Baker et al., 2012) Proposed, but far less rigorously studied in healthy or bodybuilding populations, to support lean body mass and body composition changes through GH/IGF-1 axis stimulation
Archived from the original on June 3, 2010
These compounds have no FDA-approved indication and no billing code, and insurance does not cover them